Portfolio

Algiax Pharmaceuticals researches and develops inno­vative pro­ducts for the treat­ment of diseases with high unmet medical demand. The core of the develop­ment is AP-325, a low-molecular GABA_A receptor modulator, which is currently in clinical develop­ment as a therapy for neuro­pathic pain.